Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -50.4% | 417,217.1% | – | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | -142.3% | 96% | -14,472% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -168.5% | -39.8% | -374,748.7% | – |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -190.8% | -49.1% | 14,097.8% | – |
| EPS Diluted | -1.37 | -0.89 | 0.071 | 0.042 |
| % Growth | -53.9% | -1,357.1% | 68.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |